Relmada Therapeutics (RLMD) Accumulated Expenses (2014 - 2026)

Relmada Therapeutics (RLMD) has reported Accumulated Expenses for 13 consecutive years, with $7.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 179.0% year-over-year to $7.2 million; the TTM figure through Mar 2026 stood at $7.2 million (up 179.0% YoY), while the FY2025 annual figure was $535500.0, down 26.87% from the prior year.
• Accumulated Expenses improved to $7.2 million in Q1 2026 per RLMD's latest filing, from $535500.0 in the prior quarter.
• Across five years, Accumulated Expenses topped out at $11.4 million in Q2 2022 and bottomed at $67100.0 in Q3 2023.
• Historically, Accumulated Expenses has averaged $4.2 million across 5 years, with a median of $5.4 million in 2024.
• Annual changes were most pronounced in 2022 — Accumulated Expenses soared 14797.21% — and 2023, when it sank 99.35%.
• Relmada Therapeutics' Accumulated Expenses stood at $7.2 million in 2022, then tumbled by 94.84% to $372200.0 in 2023, then soared by 96.75% to $732300.0 in 2024, then decreased by 26.87% to $535500.0 in 2025, then soared by 1237.11% to $7.2 million in 2026.
• Business Quant data shows RLMD's Accumulated Expenses at $7.2 million in Q1 2026, $535500.0 in Q4 2025, and $532600.0 in Q3 2025.